what announcement next, page-12

Neo, good news come the 1st week in May for fonda sales growth (which appears on track) will again improve the SP. Current sales of $1.5m/wk equates roughly to $25m pa to ACL. Lets assume this increases in the short term to $30m/pa to ACL or approx 10c/share earnings less 10% admin = 9c (PS quoted 10%). On a pe of 6 there's an SP around mid 50's.

Oncology has no value today on paper so a value will be created at the spin off and all holders will be beneficaries. To me a no brainer. If you are keen to sell my strategy would be sell post spin off.